Simultaneous quantification of Lopinavir and Ritonavir in tablet by HPTLC method was developed and validated. The chromatograms were developed using a mobile phase of Chloroform: 1, 4 - Dioxane (7:3 %v/v) on a pre-coated plate of silica gel GF aluminum TLC plate and quantified by densitometric absorbance mode at 210 nm. The Rf value for lopinavir and ritonavir was 0.74 and 0.58 respectively. The linearity of the method was found to be within the concentration range of 160-960 ng/spot for Lopinavir and for Ritonavir, it was 40-240 ng/spot. The lower limits of detection and quantification were 9.56 ng/spot and 28.96 ng/spot for Lopinavir and 6.82 ng/spot and 20.66 ng/spot for Ritonavir. The method was also validated for precision, specificity, and recovery. This developed method was used to analyze fixed-dose tablet (Lopimune, Cipla Ltd) sample of Lopinavir and Ritonavir.
Keywords
HPTLC, Lopinavir, Ritonavir
Cite This Article
Mardia, R.B., Suhagia, B.N., Pasha, T.Y., Chauhan, S.P., Solanki, S.D. (2012). Development and Validation of HPTLC Method for Simultaneous Analysis of Lopinavir and Ritonavir in their Combined Tablet Dosage Form, International Journal for Pharmaceutical Research Scholars, 1(1), 39-44.
INTRODUCTION
Lopinavir as [1S-[1R*, (R*), 3R*, 4R*]]-N-[4-[[(2, 6-dimethylphenoxy) acetyl] amino]-3-hydroxy-5-phenyl-1-phenylmethyl) pentyl] tetrahydro – alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide. (Fig. 1) and Ritonavir 10-Hydroxy-2-methyl-5-(1-methylethyl)-1- [2-(1 methylethyl)-4-thiazolyl] -3, 6- dioxo-8, 11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-5R*,8R*,10R*,11R*)] (Fig. 2) are anti-HIV drugs (HIV protease inhibitors). Lopinavir and Ritonavir have been reported to be quantified individually or in combination by spectrophotometric methods1–3 and HPLC4-7.
